Natera, Inc. (NASDAQ:NTRA) Insider Sells $239,075.10 in Stock

Key Points

• John Fesko, an insider at Natera, sold 1,710 shares at an average price of $139.81 on July 28, totaling over $239,000, while retaining about 151,750 shares in the company.
• Natera's stock is showing volatility with a recent trading price of $140.96, an increase of $5.12, amidst a market capitalization of $19.25 billion.
• Analysts have differing views on Natera, with price targets ranging from $170.00 to $218.00, and a consensus rating of "Moderate Buy".

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 1,710 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $239,075.10. Following the transaction, the insider owned 151,750 shares in the company, valued at approximately $21,216,167.50. This trade represents a 1.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

John Fesko also recently made the following trade(s):

• On Monday, July 21st, John Fesko sold 339 shares of Natera stock. The stock was sold at an average price of $139.29, for a total value of $47,219.31.
• On Tuesday, May 27th, John Fesko sold 1,438 shares of Natera stock. The stock was sold at an average price of $156.85, for a total value of $225,550.30.

Natera Price Performance

Natera stock traded up $0.92 during mid-day trading on Friday, hitting $134.58. 1,165,817 shares of the company's stock traded hands, compared to its average volume of 1,202,365. The firm has a 50 day simple moving average of $157.16 and a two-hundred day simple moving average of $155.88. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock has a market cap of $18.38 billion, a price-to-earnings ratio of -91.55 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company's quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.56) EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NTRA. LRI Investments LLC bought a new position in shares of Natera in the fourth quarter worth $29,000. Bank of Jackson Hole Trust bought a new position in shares of Natera in the first quarter worth $29,000. Hilltop National Bank bought a new position in shares of Natera in the second quarter worth $33,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Natera in the second quarter worth $36,000. Finally, Rakuten Securities Inc. increased its position in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares during the period. Institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent research reports. UBS Group boosted their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Evercore ISI initiated coverage on Natera in a report on Monday, July 28th. They set an "outperform" rating and a $170.00 price objective for the company. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Piper Sandler upped their price target on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Finally, Barclays upped their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and an average target price of $183.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.